Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Gastric Cancer, Metastatic Pancreatic Cancer, Metastatic Urothelial Carcinoma
Conditions
Keywords
solid tumors, CCR5
Brief summary
This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.
Detailed description
The dose escalation will use a conventional 3+3 approach, at a minimum of four planned dose levels (0.25, 0.5, 1.0, and 1.5 mg/kg), to establish a maximum tolerated dose (MTD). Additional dose levels may be investigated if PK, pharmacodynamic (PD), safety, and efficacy data indicate higher dose levels may be appropriate. The first patient - sentinel patient - at each dose level will be observed for three days before additional patients can be dosed within the same dose level. The patients will be dosed once weekly (Days 1, 8, 15, and 22) over a 4-week treatment cycle with a 28-day dose-limiting toxicity (DLT) observation period. After a full cohort has completed Day 28 assessments there will be a pause for safety evaluation conducted by the Safety Monitoring Committee (SMC). Once safety data have been reviewed, the SMC will make their recommendations to Orion who will decide whether to proceed to dosing the next dose cohort. Screening may continue during the SMC pause. Once all patients in the highest planned cohort (1.5 mg/kg OB 002) have completed Day 28 assessments, safety, PK, receptor occupancy (RO), and tolerability data will be reviewed to determine which dose level should be expanded or whether an additional dose level is needed. The expanded cohort will enrol 6 patients at the identified dose level. Patients may remain on treatment until disease progression with a follow-up (FU) period of up to 12 months. All adverse events (AEs) and non-invasive tumor assessments will be documented throughout the FU period to characterize the objective response rate (ORR) and, progression-free survival (PFS). Patients that do not complete the DLT observation period for non-DLT reasons will be replaced
Interventions
DRUGOB-002
The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
Sponsors
Orion Biotechnology Polska Sp. z o.o.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A total of up to 36 patients will be screened and 18 enrolled. At least 3 patients at each of the 4 dose levels (0.25, 0.5, 1.0, and 1.5 mg/kg planned) and up to 6 patients at the highest dose(s) if no MTD. An additional 3 patients may be recruited at any of the dose levels to define the dose(s) for further development. Each patient will be enrolled for at least one 28-day cycle of treatment with a FU period of up to 12 months.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent. 2. Patients at least 18 years of age on the day of providing consent. 3. Patients with accessible metastatic lesions for repetitive biopsy retrieval. 4. Patients with histologically or cytologically confirmed metastatic colorectal, pancreatic, gastric, breast, or urothelial tumors who have progressed or were intolerant after two or more regimens and for whom no standard of care or curative therapy options are available. 5. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 within 7 days of the start of treatment 6. Patients with evaluable and measurable lesions as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 7. Patients with adequate organ function at the time of enrollment as defined below: 1. Neutrophil count ≥1500/mm3 2. Platelet count ≥7.5 × 105/mm3 3. Hemoglobin \>9.0g/dL (transfusion \>2 weeks before testing permitted) 4. Aspartate transaminase (AST), alanine transaminase (ALT) ≤2.5 × the upper limit of normal (ULN) (≤5-times in patients with liver metastasis) 5. Total bilirubin ≤1.5 × ULN 6. Creatinine clearance \>60 mL (determined by Cockcroft-Gault Equation) 7. International normalized ratio (INR) ≤1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) 8. In women with the potential for pregnancy (including patients with amenorrhea due to medical reasons, such as chemical menopause), after consenting to the study, the patient must agree to use contraception from enrollment and for at least 12 weeks after taking the final dose of the investigational drug. Women with the potential for pregnancy include those who have begun menstruation, who have not undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, and who have not gone through menopause. Menopause is defined as the consecutive absence of menstrual periods for ≥12 months. Total abstinence is an acceptable mode of contraception. 9. In the case of men, the patient must agree after consenting to the study to use contraception from enrollment and for at least 13 weeks after taking the final dose of the investigational drug (a period of 90 days \[the spermatogenesis cycle\] is added to 5-times the elimination half-time of I/O agent. Total abstinence is an acceptable mode of contraception.
Exclusion criteria
1. Unwilling to undergo biopsy retrieval during screening (unless an archival sample taken within 3 months before screening is available) and after the fourth infusion of OB-002 2. Patients who have undergone systemic chemotherapy, radiotherapy, surgery, or hormone therapy \<28 days before enrollment, also see exclusion criterion #8. Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Patients with ≤Grade 2 neuropathy may be eligible. If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. 3. Patients with a history of CCR5 antagonist therapy (e.g., vicriviroc, maraviroc). 4. Patients with uncontrolled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg) with treatment 5. QTc interval greater than 450 msec (males) or 470 msec (females) 6. Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment 7. Patients with a large amount of pleural effusion or ascites requiring more than weekly drainage 8. Patients with a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis. 9. Patients with a ≥Grade 3 active infection according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 10. Patients with symptomatic brain metastasis (1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system \[CNS\] disease) 11. Patients with partial or complete gastrointestinal obstruction 12. Patients with interstitial lung disease requiring treatment with systemic steroids or other agents 13. Patients who test positive for either anti-human immunodeficiency virus type 1 (HIV-1) antibodies, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies with a positive HCV RNA viral load test 14. Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease 15. Patients who require systemic corticosteroids equivalent to ≥10 mg prednisone (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy) or immunosuppressants, or who have received such a therapy \<14 days before enrollment in the present study 16. Patients with a history or findings of ≥Grade 3 congestive heart failure according to the New York Heart Association functional classification 17. Patients with a seizure disorder who require pharmacotherapy 18. Persistent proteinuria \>3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (≥Grade 3, NCI CTCAE v5.0) 19. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation 20. Major surgical procedure or significant traumatic injury within 28 days before the start of study medication 21. Non-healing wound, non-healing ulcer, or non-healing bone fracture 22. Patients with evidence or history of any bleeding diathesis, irrespective of severity 23. Any hemorrhage or bleeding event ≥Grade 3 (NCI CTCAE v 5.0) within 4 weeks prior to the start of the study medication 24. Women who are pregnant or breastfeeding, or with the potential for pregnancy unwilling to undergo contraception 25. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety: adverse events | From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Number of patients experiencing adverse events (AEs), serious AEs (SAEs) abnormalities in clinical laboratory tests, vital signs, electrocardiograms (ECGs), and physical exams |
| Safety: Maximum Tolerated Dose | From date of first infusion with 28 days observation period (+/-3 days) | MTD will be defined on the basis of dose-limiting toxicities (DLTs) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| (PK) Pharmacokinetics AUC0-t | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with area under the curve from time 0 to last sampling time (AUC0-t) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. |
| (PK) Pharmacokinetics AUC0 ∞ | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with area under the curve from time 0 to infinity (AUC0 ∞) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. |
| (PK) Pharmacokinetics Cmax | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with maximum observed concentration (Cmax) profile of OB-002 in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. |
| (PK) Pharmacokinetics Vd | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with the volume of distribution (Vd) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. |
| (PK) Pharmacokinetics CL | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with clearance (CL) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. |
| (PK) Pharmacokinetics t1/2 | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with terminal half-life (t1/2) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. |
| (PK) Pharmacokinetics Tmax | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with time to maximum serum concentration (Tmax) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory: evaluation of OB-002 on blood biomarkers (chemokines) | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Systemic monitoring of secreted chemokines. |
| Exploratory: evaluation of OB-002 on tumor biomarkers (tumor-associated immune cells in TMI) | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Examination of tumor-associated immune cells in tumor microenvironment |
| Exploratory: immunogenicity of OB-002 | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | A number of patients developing antidrug antibodies (ADA) and the titers developed in these participants. |
| Exploratory: evaluation of OB-002 on blood biomarkers (ctDNA) | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Plasma circulating tumor DNA (ctDNA) analysis |
| Exploratory: evaluation of OB-002 on blood biomarkers (TCR) | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Genomic analyses on whole blood/peripheral blood mononuclear cells (PBMC) for T-cell repertoire (TCR) analyses |
| Exploratory: evaluation of receptor occupancy (RO) of OB-002 in blood | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | Percent of CCR5 receptors occupied by OB-002 in blood |
| Exploratory: evaluation of receptor occupancy (RO) of OB-002 in tumor | samples are collected from first to fourth infusion (period of 28 days +/- 2 days) | Percent of CCR5 receptors occupied by OB-002 in tumor biopsies |
| Exploratory: preliminary efficacy of OB-002 as monotherapy based on best overall response | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months | Objective response rate (ORR): defined as the proportion of patients having best overall response (BOR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. |
| Exploratory: preliminary efficacy of OB-002 as monotherapy based on complete response | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months | Objective response rate (ORR): defined as the proportion of patients having complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. |
| Exploratory: preliminary efficacy of OB-002 as monotherapy based on partial response | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months | Objective response rate (ORR): defined as the proportion of patients having a partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. |
| Exploratory: preliminary efficacy of OB-002 as monotherapy based on Progression-free survival | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months | Progression-free survival (PFS): defined as the time from randomization until objective tumor progression or death, whichever comes first by RECIST v1.1 |
| Exploratory: evaluation of OB-002 on blood biomarkers (immune cells) | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Systemic monitoring of circulating immune cells |
| Exploratory: evaluation of OB-002 on blood biomarkers (cytokines) | From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Systemic monitoring of secreted cytokines. |
Outcome results
None listed